Patents by Inventor Kristin Thompson

Kristin Thompson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNA POLYMERASE FOR SYNTHESIS OF MODIFIED RNA
    Publication number: 20220056425
    Abstract: The present disclosure provides T7 RNA polymerase variants with enhanced transcriptional activity, and methods of using such variants to produce modified oligonucleotides, such as 2?-modified oligonucleotides. These polymerase variants and methods thereof improve the transcription yield of modified oligonucleotides.
    Type: Application
    Filed: September 12, 2019
    Publication date: February 24, 2022
    Inventors: Kristin THOMPSON, Yuxun WANG, Shuhao ZHU
  • Materials and methods for the generation of fully 2?-modified nucleic acid transcripts
    Patent number: 8105813
    Abstract: Materials and methods are provided for producing aptamer therapeutics having fully modified nucleotide triphosphates incorporated into their sequence.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: January 31, 2012
    Assignee: Archemix Corp.
    Inventors: John L. Diener, Anthony Dominic Keefe, Kristin Thompson, Chunhua Wang, Shuhao Zhu
  • Materials and methods for the generation of transcripts comprising modified nucleotides
    Patent number: 8101385
    Abstract: Materials and methods are provided for producing aptamer therapeutics having modified nucleotide triphosphates incorporated into their sequence.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: January 24, 2012
    Assignee: Archemix Corp.
    Inventors: Sharon Cload, John L. Diener, Anthony Dominic Keefe, Kristin Thompson
  • Aptamer therapeutics useful in the treatment of complement-related disorders
    Patent number: 7803931
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Grant
    Filed: February 14, 2005
    Date of Patent: September 28, 2010
    Assignee: Archemix Corp.
    Inventors: Claude Benedict, John Diener, David Epstein, Dilara Grate, Sara Chesworth Keene, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman, Kristin Thompson, Charles Wilson, Anna J. Zoltoski
  • Materials and methods for the generation of transcripts comprising modified nucleotides
    Publication number: 20100120024
    Abstract: Materials and Methods are provided for producing aptamer therapeutics having modified nucleotide triphosphates incorporated into their sequence.
    Type: Application
    Filed: December 21, 2007
    Publication date: May 13, 2010
    Inventors: Sharon Cload, John L. Diener, Anthony Dominic Keefe, Kristin Thompson
  • GENE KNOCK-DOWN BY INTRACELLULAR EXPRESSION OF APTAMERS
    Publication number: 20090258425
    Abstract: Materials and Methods are provided for target validation by gene knock-down with intracellularly expressed aptamers and siRNAs. The aptamers produced by the materials and methods of the invention are useful in target validation for therapeutics development.
    Type: Application
    Filed: June 17, 2009
    Publication date: October 15, 2009
    Inventors: David Epstein, Harold Nicholas Marsh, Shannon Pendergrast, Kristin Thompson
  • Aptamer therapeutics useful in the treatment of complement-related disorders
    Patent number: 7538211
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: May 26, 2009
    Assignee: Archemix Corp.
    Inventors: Claude Benedict, John Diener, David Epstein, Dilara Grate, Sara Chesworth Keene, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman, Kristin Thompson, Charles Wilson, Anna J. Zoltoski
  • Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
    Publication number: 20090082555
    Abstract: The present invention provides materials and methods to treat immune disease in which cytokines are involved in pathogenesis. The materials and methods of the present invention are useful in the treatment of autoimmune diseases. The materials and methods of the present invention are directed to nucleic acid ligands capable of binding to human IL-23 and/or human IL-12 cytokines and thus modulate their biological activity and are useful as therapeutic agents in immune, auto-immune and cancer therapeutics.
    Type: Application
    Filed: June 9, 2008
    Publication date: March 26, 2009
    Inventors: John L. Diener, Alicia Ferguson, Nobuko Hamaguchi, Sara Chesworth Keene, H.A. Daniel Lagasse, Pooja Sawhney, Kristin Thompson
  • Metabolic profile directed aptamer medicinal chemistry
    Publication number: 20090075342
    Abstract: The present invention provides materials and methods for enhancing aptamers. More specifically, the materials and methods of the present invention are directed toward the modification of aptamers by the identification of one or more cleavage sites, and introduction of a chemical substitution at a position proximal to the cleavage site(s). Such aptamers are useful for the treatment of disease, in diagnostic and detection applications, and/or research, e.g., target validation.
    Type: Application
    Filed: April 30, 2008
    Publication date: March 19, 2009
    Inventors: Sharon Cload, Christine P. Donahue, Renta Hutabarat, Kristin Thompson, Charles Wilson
  • Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
    Publication number: 20070117112
    Abstract: Materials and methods are provided for producing aptamer therapeutics having fully modified nucleotide triphosphates incorporated into their sequence.
    Type: Application
    Filed: June 30, 2006
    Publication date: May 24, 2007
    Inventors: John Diener, Anthony Keefe, Kristin Thompson, Chunhua Wang, Shuhao Zhu
  • Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
    Publication number: 20070066550
    Abstract: The present invention provides materials and methods to treat immune disease in which cytokines are involved in pathogenesis. The materials and methods of the present invention are useful in the treatment of autoimmune diseases. The materials and methods of the present invention are directed to nucleic acid ligands capable of binding to human IL-23 and/or human IL-12 cytokines and thus modulate their biological activity and are useful as therapeutic agents in immune, auto-immune and cancer therapeutics.
    Type: Application
    Filed: March 7, 2005
    Publication date: March 22, 2007
    Inventors: John Diener, Alicia Ferguson, Nobuko Hamaguchi, Sara Keene, H.A. Lagasse, Pooja Sawhney, Kristin Thompson
  • Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
    Publication number: 20060193821
    Abstract: The present invention provides materials and methods to treat immune disease in which cytokines are involved in pathogenesis. The materials and methods of the present invention are useful in the treatment of autoimmune diseases. The materials and methods of the present invention are directed to nucleic acid ligands capable of binding to human IL-23 and/or human IL-12 cytokines and thus modulate their biological activity and are useful as therapeutic agents in immune, auto-immune and cancer therapeutics.
    Type: Application
    Filed: September 22, 2005
    Publication date: August 31, 2006
    Inventors: John Diener, David Epstein, Alicia Ferguson, Nobuko Hamaguchi, H.A. Lagasse, Shannon Pendergrast, Pooja Sawhney, Kristin Thompson
  • Aptamer therapeutics useful in the treatment of complement-related disorders
    Publication number: 20060105980
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Application
    Filed: December 22, 2005
    Publication date: May 18, 2006
    Inventors: Claude Benedict, John Diener, David Epstein, Dilara Grate, Sara Keene, Jeffrey Kurz, Markus Kurz, Thomas McCauley, James Rottman, Kristin Thompson, Charles Wilson, Anna Zoltoski
  • Controlled modulation of the pharmacokinetics and biodistribution of aptamer therapeutics
    Publication number: 20060030535
    Abstract: Materials and methods are provided to modulate, in a controlled manner, the pharmacokinetic and biodistribution properties of nucleic acid aptamers, and to enhance their safety and efficacy properties as therapeutic agents.
    Type: Application
    Filed: March 7, 2005
    Publication date: February 9, 2006
    Inventors: Judith Healy, Markus Kurz, Thomas McCauley, Kristin Thompson, Charles Wilson, Dorothy Margolskee
  • Aptamer therapeutics useful in the treatment of complement-related disorders
    Publication number: 20060018871
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Application
    Filed: February 14, 2005
    Publication date: January 26, 2006
    Inventors: Claude Benedict, John Diener, David Epstein, Dilara Grate, Sara Keene, Jeffrey Kurz, Markus Kurz, Thomas McCauley, James Rottman, Kristin Thompson, Charles Wilson, Anna Zoltoski
  • Gene knock-down by intracellular expression of aptamers
    Publication number: 20050250106
    Abstract: Materials and methods are provided for target validation by gene knock-down with intracellularly expressed aptamers and siRNAs. The aptamers produced by the materials and methods of the invention are useful in target validation for therapeutics development.
    Type: Application
    Filed: April 23, 2004
    Publication date: November 10, 2005
    Inventors: David Epstein, Harold Marsh, Shannon Pendergrast, Kristin Thompson
  • Regulatable, catalytically active nucleic acids
    Publication number: 20040126882
    Abstract: Compositions and methods are provided to make, isolate, characterize and use regulatable, catalytically active nucleic acids (RCANA). The present invention is directed to RCANA that transduce molecular recognition into catalysis. Also, RCANAs according to the invention can be used as regulatory elements to control the expression of one or more genes in a metabolic pathway. RCANAs can also be used as regulated selectable markers to create a selective pressure favoring (or disfavoring) production of a targeted bioproduct.
    Type: Application
    Filed: September 24, 2002
    Publication date: July 1, 2004
    Inventors: Andrew D. Ellington, Jay Hesselberth, Kristin Thompson, Michael P. Robertson, Letha Sooter, Eric Davidson, J. Colin Cox, Timothy Riedel, Charles Wilson, Sharon T. Cload, Anthony D. Keefe